Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition - Takeaways - MDSpire

Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition

  • By

  • Yijia Li

  • Michael B Townsend

  • Shanshan Li

  • Quinn E Testa

  • Tom Medvec

  • Elizabeth A Thompson

  • Frank J Palella

  • Matthew J Mimiaga

  • James B Brock

  • Maria L Alcaide

  • Anandi N Sheth

  • Michelle Floris-Moore

  • Aruna Chandran

  • Audrey L French

  • Phyllis C Tien

  • Daniel J Merenstein

  • Michael Augenbraun

  • Anjali Sharma

  • Caitlin A Moran

  • Charles R Rinaldo

  • Bernard J C Macatangay

  • Panayampalli S Satheshkumar

  • Ken S Ho

  • August 14, 2025

  • 0 min

Share

  • 1

    The study assessed immune responses to MVA-BN vaccination in 114 older individuals with or at risk for HIV.

  • 2

    MVA-BN vaccination induced sustained IgG levels for up to one year, regardless of HIV status.

  • 3

    Participants born before 1973 exhibited higher IgG levels compared to younger individuals.

  • 4

    Unvaccinated individuals with HIV had lower IgG levels than those without HIV.

  • 5

    This research highlights the need for further studies on long-term immunogenicity of MVA-BN in vulnerable populations.

Original Source(s)

Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition

  • by Yijia Li, Michael B Townsend, Shanshan Li, Quinn E Testa, Tom Medvec, Elizabeth A Thompson, Frank J Palella, Matthew J Mimiaga, James B Brock, Maria L Alcaide, Anandi N Sheth, Michelle Floris-Moore, Aruna Chandran, Audrey L French, Phyllis C Tien, Daniel J Merenstein, Michael Augenbraun, Anjali Sharma, Caitlin A Moran, Charles R Rinaldo, Bernard J C Macatangay, Panayampalli S Satheshkumar, Ken S Ho

  • August 14, 2025

Related Content

SARS-CoV-2 in Pregnancy—More Hints of Rare Complications

HHS appeals ruling that stalled many of Kennedy’s vaccine policy changes

Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population